

## **ASX Announcement**

### **7 June 2023**

### ***CORRECTION TO DIRECTORS INTEREST NOTICES***

Elixinol Wellness Limited (**Elixinol Wellness** or the **Company**) (**ASX:EXL**) advises that there were typographical errors in the Appendix 3Y lodged regarding the holdings of Helen Wiseman on 31 May 2023 (regarding the number of securities held after the change) and the Appendix 3Z lodged regarding the holdings of Paul Benhaim on 6 April 2023 (regarding the date of the last notice).

Corrected copies of the lodgments are attached, replacing the lodgments outlined above.

This document was authorised to be given to the ASX by the Board of the Company.

#### **Investor relations please contact:**

Ron Dufficy, Group CEO & Managing Director  
[ron.dufficy@elixinolwellness.com](mailto:ron.dufficy@elixinolwellness.com)

#### **About Elixinol Wellness**

Elixinol Wellness Limited (ASX: EXL) is a pioneer in the global hemp industry, innovating, marketing and selling hemp and other plant-derived nutraceutical, cosmetic and food products. The Company's simplified business model is focusing on:

- In the Americas, innovating, marketing and selling high quality Elixinol branded hemp and other plant-derived nutraceutical and skincare products based in Colorado, USA
- In Australia, Hemp Foods Australia is a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products
- In the United Kingdom, South Africa, Japan, Brazil, Mexico and Malaysia (pending approvals), branded hemp and other plant-derived products are available to consumers via exclusive Distribution and/or Trademark and Know-How Licensing Agreements
- Across the Rest of World, expanding distribution of branded hemp and other plant-derived products through reputable distributors as key markets open.

See more at [www.elixinolwellness.com](http://www.elixinolwellness.com)

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity:</b>	Elixinol Wellness Limited
<b>ABN:</b>	621 479 794

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Helen Wiseman
<b>Date of last notice</b>	6 January 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	1) 26 May 2023 2) 31 May 2023
<b>No. of securities held prior to change</b>	280,132 Fully paid Ordinary Shares 1,043,424 Performance Share Rights
<b>Class</b>	1) Fully paid Ordinary Shares 2) Director Fee rights
<b>Number acquired</b>	1) 555,556 Fully paid Ordinary Shares 2) 3,055,556 Director Fee rights
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	1) Ordinary Shares - \$0.018 per share 2) Director Fee rights - issued in lieu of cash consideration with a deemed issue price of \$0.018 per Director Fee Right.

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>No. of securities held after change</b>	835,688 Fully paid Ordinary Shares 1,043,424 Performance Share Rights 3,055,556 Director Fee rights
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1) Fully paid ordinary shares issued under the Company's Share Purchase Plan 2) Issue of Director Fee rights approved by shareholders at the Company's Annual General Meeting on 31 May 2023

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

If prior written clearance was provided, on what date was this provided?	N/A
--	-----

---

+ See chapter 19 for defined terms.

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity:</b>	<b>Elixinol Wellness Limited</b>
<b>ABN:</b>	<b>621 479 794</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Paul Benhaim
<b>Date of last notice</b>	28 February 2023
<b>Date that director ceased to be director</b>	6 April 2023

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
Nil Performance Share Rights, (following lapse of performance rights upon departure from office)

+ See chapter 19 for defined terms.

**Part 2 – Director's relevant interests in securities of which the director is not the registered holder**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest</small>	<b>Number &amp; class of securities</b>
Raw With Life Pty Ltd ACN 116 090 987 as trustee for the Benhaim Trading Trust, of which Mr Benhaim is a beneficiary.	29,209,217 Fully Paid Ordinary Shares.

**Part 3 – Director's interests in contracts**

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>No. and class of securities to which interest relates</b>	N/A

+ See chapter 19 for defined terms.